MASHINIi

Septerna, Inc..

SEPN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Septerna, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel small molecule medicines targeting G protein-coupled receptors (GPCRs). GPCRs are a large and diverse family of signaling proteins that mediate cellular responses to a wide range of stimuli and ar...Show More

Ethical Profile

Mixed.

Septerna, Inc. is advancing oral small molecule drugs for diseases including obesity, hypoparathyroidism, and type 2 diabetes, supported by a substantial $200 million upfront investment from Novo Nordisk, with potential milestones reaching $2.2 billion, aiming to enhance health accessibility. Regarding environmental impact, Septerna participates in a lab plastics recycling program, diverting 247 kg of plastic from landfills, though comprehensive waste reduction targets are not publicly detailed. As a clinical-stage biotech, Septerna likely utilizes animal testing for preclinical drug development, with specific animal welfare policies not fully disclosed. Information on fair pay, ethical sourcing, and community engagement remains limited.

Value Scores

Better Health for All30
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

30

Septerna is a clinical-stage biotechnology company developing oral small molecule drugs for various diseases, aligning with the goal of better health for all. The company's pipeline includes treatments for hypoparathyroidism, chronic spontaneous urticaria, Graves' disease, obesity, and type 2 diabetes

1
. A collaboration with Novo Nordisk provides $200 million upfront and potentially $2.2 billion in milestone payments, indicating significant investment in health innovation
2
,
3
. Septerna's focus on oral drugs could improve accessibility compared to injectables
4
. However, there is limited information on price accessibility, vulnerable population reach, and specific health equity programs
5
,
6
. The company's privacy policy commits to ethical data practices
7
. Given the potential for positive health impact and significant R&D investment, but a lack of information on accessibility and equity, a score of +30 is appropriate. A higher score would require more evidence of accessibility and affordability initiatives.

Fair Money & Economic Opportunity

0

No evidence available to assess Septerna, Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

As of December 31, 2024, Septerna had 75 full-time employees.

1
The company states that all full-time employees are eligible to participate in employee benefit and insurance programs, including health insurance.
2
This indicates 100% health insurance coverage for its full-time workforce. Additionally, the company's workforce consists of 75 full-time employees, implying that 0% of its workforce is on temporary, zero-hour, or gig contracts without benefits. None of Septerna's employees are represented by labor unions or covered by collective bargaining agreements, and the company considers its relationship with its employees to be good.
3
No specific, quantitative evidence was found for living wage coverage, CEO to median pay ratio, safety incident rate, pay equity ratio, worker engagement score, turnover rate, or labor violation incidents.
4

Fair Trade & Ethical Sourcing

0

The provided articles, including Septerna, Inc.'s Code of Business Conduct and Ethics, do not contain any specific quantitative data, regulatory actions, violations, fines, certifications, or industry comparisons relevant to the 'Fair Trade & Ethical Sourcing' KPIs.

1
No information was found for fair_trade_cert_share, audit_frequency, forced_child_labour_incidents, traceability_coverage, remediation_speed, ethical_clause_coverage, materials_risk_index, or supplier_diversity_spend.
2
General policies on ethical conduct or legal compliance are not sufficient to score against the rubric's quantitative thresholds.

Honest & Fair Business

0

No specific, concrete data points were found in the provided articles for any of the KPIs related to Honest & Fair Business. The articles explicitly state that information for regulatory fines, transparency index, whistleblower policy, financial restatements, audit coverage, ESG controversy index, complaint resolution time, board conflict-free percentage, anti-corruption policy, and third-party verification was not available or not contained within the provided text.

1

Kind to Animals

0

No specific, concrete data points were found in the provided articles for Septerna, Inc. that directly map to the quantitative thresholds of the 'Kind to Animals' ethical value KPIs. While one article mentioned the use of 'Primary human renal proximal epithelial cells and a human osteoblast cell line' in preclinical studies, and 'preclinical safety studies' involving 'mouse bones', this information does not provide sufficient quantitative detail (e.g., percentage of alternative testing, number of animals used annually, or specific policy strength) to assign a score against the rubric's defined tiers.

1
Other articles focused on general company information, financial partnerships, or the broader regulatory landscape regarding animal testing (FDA policies), rather than Septerna's specific practices, certifications, or volumes related to animal welfare.

No War, No Weapons

0

No evidence available to assess Septerna, Inc. on No War, No Weapons.

Planet-Friendly Business

0

No specific, concrete data points related to planet-friendly business metrics, environmental performance, or sustainability initiatives were found in the provided articles for Septerna, Inc. The articles primarily focus on the company's financial results, drug discovery platform, pipeline, funding, and corporate overview.

Respect for Cultures & Communities

0

No specific, concrete data points or evidence regarding Septerna, Inc.'s performance on any of the 'Respect for Cultures & Communities' KPIs were found in the provided articles.

1
The articles primarily discuss the company's research pipeline or are unavailable/irrelevant to community engagement metrics.

Safe & Smart Tech

0

Septerna's privacy policy outlines user rights to access, correct, delete, and limit data use.

1
Privacy principles are mentioned as part of the company's development process.
2
The company also states compliance with the CCPA.
3
No specific details or quantitative metrics are provided regarding the effectiveness, scope, or implementation of these measures, nor is there evidence for data breaches, cybersecurity investments, or AI ethics.
4

Zero Waste & Sustainable Products

0

The provided articles do not contain specific, quantitative evidence directly attributable to Septerna, Inc. regarding its performance across any of the 'Zero Waste & Sustainable Products' KPIs.

1
2
Information found pertains to general industry trends, third-party initiatives, or other companies, without direct attribution or specific metrics for SEPN.US. Therefore, no KPIs can be scored based on the given evidence.

Own Septerna, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.